AROG Pharmaceuticals ARO-013, Phase III Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy of the Addition of Crenolanib to Salvage Chemotherapy Versus Salvage Chemotherapy Alone in Subjects ≤ 75 Years of Age with Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemia

September 17, 2018
https://clinicaltrials.gov/ct2/show/NCT03250338
Cancer - Leukemia
Principal Investigator: Yue Guo, MD
myeloid, leukemia, FLT3
Accepting Participants